US3902964A - Method of and apparatus for chemically separating plasma or serum from formed elements of blood - Google Patents
Method of and apparatus for chemically separating plasma or serum from formed elements of blood Download PDFInfo
- Publication number
- US3902964A US3902964A US362454A US36245473A US3902964A US 3902964 A US3902964 A US 3902964A US 362454 A US362454 A US 362454A US 36245473 A US36245473 A US 36245473A US 3902964 A US3902964 A US 3902964A
- Authority
- US
- United States
- Prior art keywords
- blood
- positively charged
- lectin
- charged polymer
- elements
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5002—Partitioning blood components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/491—Blood by separating the blood components
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D21/00—Separation of suspended solid particles from liquids by sedimentation
- B01D21/01—Separation of suspended solid particles from liquids by sedimentation using flocculating agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
Definitions
- This invention relates to the separation of formed elements of the blood from plasma or serum.
- chanical separation techniques including centrifuging are cumbersome in that they require rather elaborate mechanical apparatus. Moreover, mechanical separation techniques may provide somewhat less than optimum plasma or serum yields. In addition, mechanical separation techniques can result in faulty plasma or serum analysis due to the time involved in transporting a blood sample to a centrifuging apparatus thereby delaying the separation of plasma or serum from the formed elements of the blood.
- separation of the cells from the plasma or serum should take place immediately thereby decreasing the amount of serum or plasma contamination by cell breakdown.
- agglutinating agent comprising a positively charged polymer such as Polybrene (hexadimcthrine bromide).
- Polybrene hexadimcthrine bromide
- Precipitation of the blood agglutinated with Polybrene into fairly large clumps is very slow without centrifuging.
- the total amount of plasma or serum which may be obtained with Polybrene is relatively small.
- the total volume of serum which may be obtained in a given length of time is small as compared with the volume obtained utilizing the phytohemagglutinin described by Brewer.
- the longer the blood cells remain in the plasma the greater the contamination of the plasma so as to adversely affect the plasma analysis.
- a good deal of debris will remain in suspension in the plasma after precipitation. Any attempt to increase the concentration of Polybrene beyond a certain point for speeding precipitation will result in lysis of the blood cells.
- two chemical reagents are utilized to cause agglutination of the formed elements of the blood and precipitation of these elements from the plasma or serum of the blood.
- the reagents comprise a positively charged polymer (basic polyelectrolyte) such as Polybrene, and a lectin (hemagglutinin plant extract), such as Bacto Phytohcmagglutinin P. which are added to a blood collection tube either during the manufacturing of the tube or at a later time by, for example, conventional needle insertion techniques.
- the blood taken from the donor is re ccived within the tube and the plasma is separated out as a result of the action of the above-mentioned chemi cals with the blood.
- the separation mechanism occurs spontaneously within one-half hour or less.
- the chemical reagents create large three dimensional dense clumps of blood cells which readily precipitate to the bottom of the collection tube. These clumps are desirable in that they are not easily broken apart by jarring the blood sample.
- a lectin has an increased agglutinating ability in the presence of a positively charged polymer. Since the formed elements of the blood are all negatively charged, they tend to repel one another and the probability of the lectin attached to a receptor site on one cell coming into contact with a receptor site of another cell to form a clump is lowered by this mutual repulsion.
- the cells and polymer form neutralized masses which permit the lectin to more effectively agglutinate the blood cells since the cells are more likely to come into sufficiently close contact to permit the lectin to form links between the cells at receptor sites and cells within a clump are able to move into a densely packed configuration due to the absence of repulsion.
- the positively charged polymer also provides its own agglutinating function.
- the single cell within the clump may be linked to one or more cells by the lectin while the same cell is linked to one or more other cells by the positively charged polymer.
- each cell is able to be attached to a greater number of cells than would be the case if only one of the two different types of agglutinating agents were utilized.
- This agglutinating mechanism also helps create increased density of cells in a clump and larger three dimensional clumps.
- the large three dimensional clumps are essentially large net-like structures which are capable of dragging debris and fibrin down through the plasma. As the clumps collect at the bottom of the collection tube, a substantially integral structure is formed wherein all of the individual clumps are connected to one another.
- FIG. la is an elevational view of a container immediately after blood, lectin and a positively charged polymer have been combined in accordance with this invention.
- FIG. 1/ is an elevational view of the container and the contents of FIG. Ia approximately l minutes later;
- FIG. 2a is an elevational view of a container immediately after blood and a lectin have been combined
- FIG. 2b is an elevational view of the container and the contents of FIG. 2a approximately minutes later;
- FIG. 3a is an elevational view of a container immediately after blood and a positively charged polymer have been combined
- FIG. 3b is an elevational view of the container of FIG. approximately 15 minutes later;
- FIG. 4 is a schematic illustration of a clump of blood cells agglutinated in accordance with this invention.
- FIG. 4a is a schematic illustration of a clump of blood cells agglutinated with a positively charged polymer
- FIG. 4b is a schematic illustration of a clump of blood cells agglutinated with an organic hemagglutinin.
- the probability of the lectin attaching to a receptor site and one of the cells coming into contact with a receptor site of another cell to form a clump is lowered by this mutual repulsion.
- the negative cells are attracted to the Polybrene to create substantially electrically neutralized blood cellpolymer combinations.
- the lectin which attaches to the blood cell is then better able to agglutinate the blood cells and to clump since it does not have to overcome or otherwise work against the repulsion forces between the negatively charged blood cells since the blood cells have in effect been neutralized by the Polybrene.
- large, dense. three dimensional clumps of red blood cells are formed which rapidly precipitate to the bottom of the sample container.
- the clumps of blood cells are very durable in that they do not break-up when the sample container is shaken, jarred or otherwise stirred. It is believed that this reflects the strength of the lectin agglutinating link between blood cells which no longer has to overcome the repulsion of the blood cells due to the neutralization by the Polybrene.
- the very dense nature of the clumps is to be attributable to the fact that the lectin is capable of upholding the blood cells in a closely linked relationship since the cells are no longer repelling one another again due to the neutralization by the positively charged polymer.
- the long axis of the collection tube is placed parallel to the surface of acounter top. After the separation has taken place. the tube is gradually rotated manually to dislodge and put into solution any cells that remain on the glass part of the tube or stopper. A rotation of the tube also aids in filtering out the fibrin in the plasma to leave serum. The long axis of the tube is then placed perpendicular to the counter top.
- a substance can be added to inhibit the formation of fibrin or destroy the formation.
- a substance may also be added to cause clotting and precipitate the fibrin once it is present.
- Fibrinolysin may be added to the collection tube to prevent the formation of fibrin, or a clotting agent such as thrombin may be added to accelerate clotting of the fibrin.
- the clumped blood cells which form a net-like structure effectively drag the fibrin downwardly with the clump of formed blood elements to in effect filter, at least to some degree, the fibrin out of the plasma.
- FIG. Ia shows a collection tube filled with a blood sample substantially immediately after the blood sample has been combined with Polybrene and Bacto Phytohemagglutinin P. Note that the formed elements of the blood near the bottom of the tube have begun to precipitate as can be seen from the light region 12 which represents plasma and a relatively low concentration of the formed blood elements.
- Microscopic examination of the clumps 14 indicates that they are substantially three dimensional structures comprising densely packed blood cells. After 15 minutes have passed. a layer 12' of plasma is achieved about 997: of the precipitated, formed elements of the blood. In this interim, a substantial number of the clumps on the wall of the tube 10 have slid down the wall through the plasma l2 and into the precipitated elements at the bottom of. the tube I0. Note that the clumps I4 which remain on the wall of the tube I0 are much larger than the clumps 14 which existed immediately after the blood had been combined with the Polybrene and the Bacto Phytohemagglutinin P.
- FIG. 2a is a tube filled with a blood sample immediately after it has been combined with Bacto Phytohemagglutinin P. alone without the Polybrene being present.
- a layer of plasma 22 has begun to form near the top of the blood sample due to the immediate precipitation within the sample as a result of the clumps of blood elements which are created by the Bacto Phytohemagglutinin P.
- the clumps 24 on the walls of the tube 20 indicate that the Bacto Phytohemagglutinin P. produces much smaller clumps than those produced by the combination of the Polybrene and the Bacto Phytohemagglutinin P.
- clumps 24 remain on the walls of the tube 20 after 15 minutes of precipitation. Furthermore, these clumps are of substantially the same size of the clumps 24 shown in FIG. 2a. In other words, the size of the clumps does not increase with time and the clumps do not become large enough to slide under the influence of gravity down the walls of the tube 20.
- the amount of plasma 12 obtained utilizing the combined agglutinating substances of the invention as shown in FIG. lb - is much more than the sum of the plasma obtained from utilizing either of those agglutinating agents alone as shown in FIGS. 2b and 3b.
- Actual measurements indicate that the amount of plasma 12' obtained utilizing this invention is approximately twice the amount of plasma obtained in utilizing the individual ingredients alone as depicted in FIGS. 2b and 3b.
- the result achieved in utilizing the combination: of the Polybrene and the Bacto Phytohemagglutinin P. is more than (approximately twice) the sum of the results achieved when utilizing these two ingredients separately.
- FIG. 4 depicts a fragile clump of blood cells 40 which are linked on to one another by polymeric seams schematically depicted by the symbol .r. Note that each of the blood cells 40 is linked to at least one other blood cell by the polymeric seam .t and those blood cells 40 in the middle of the clump are linked totwo or three blood cells. However, each blood cell does have a substantial surface area which is not adjacent, in contact or connected to any other blood cell.
- each negatively charged blood cell 40 is capable of being attracted to 'a limited number of positively charged polymers before the overall charge on the combination polymerblood cell is neutralized so as to prevent the attraction of that particular blood cell to any other positively charged polymers.
- FIG. 4b depictsa somewhat-smaller clump than that shown in FIG. 4a wherein the agglutination is achieved by a lectin.-
- FIG. 412 four cells 44 are linked or bonded as depicted by the symbol 0.
- the nature of the link is not particularly well understood but one very plausible explanation has been offered in the aforesaid Liener article which suggests that each blood cell includes a limited number of receptor sites to which a hemagglutinin such as Bacto PhytohemagglutininP. may be attached.
- the large, dense-clump of blood cells 46 is formed by a substantial number of individual blood cells which are completely surrounded by other blood cells and attached thereto by a plurality of lectin links 0.
- the positively charged polymer forms bonds or seams .r between blood cells'in the clump so as to perform the dual function of increasing the agglutinating ability of the lectin while also providing its own agglutinating function.
- FIG.4 When the clump in FIG.4 is analyzed, it will be seen that a substantial number of the blood cells in the clump have both a lectin link 0 and a polymer scam-A- with other blood cells.
- the size of the clumps is not the only factt'irwhich determines the rate and extent of precipitation. If'itwere, the positively charged polymer alone would precipitate more rapidly than the organic lectin alone which'would be inconsistent-with the experimental results depicted in FIGS. 2b and 3b.
- the large, spider-like clumps of blood cells an example of which is depicted in FIG. 4u,cr'eate a type of structure in the blood sample which is not only slow to precipitate but actually self-supporting due to the formation of fibrin soaasto account for the rather shallow layer of plasma 32' which is obtained when utilizing the positively charged polymer alone as depicted'in FIG. 3b.
- the combination of the positively charged polymer and the lectin achieves a dense cl-ump which precipitates 'rapidly and collapses into a rather limited area so as to obtain arather deep layer of plasma 12' as depicted in FIG. 119 due to the inhibition of fibrin formation.
- This explanation is borne out by microscopic examination of the blood cells at the bottom of the tube 10 when the combination of the positively charged polymer and the lectin is utilized.
- the blood cells at the bottom of the tube 10 as depicted in'FIG. lb seems to be a substantially unitary orintegra'l mass of compact blood cells which cling together when the tube 10 is tipped, shaken, jarred or otherwise disturbed.
- clumps ofblood cells precipitated to the bottom of containers 20'and are not'part of an -integral mass and se'paratefrom one another when the tube is disturbed.
- rapid precipitation of the blood cells is achieved while preserving the integrity of the tests results and analysis of the plasma.
- the chart reproduced below represents actual test results of my system (M.'S.) compared with the presently used conventional centrifuged system (C.S.).
- a random selection of blood donors was used, and the blood samplings from the centrifuged system were obtained by using'the standard Becton-Dickinson tubes and reagents.
- My system Polybrene andBacto Phytohemaggliltinin P. were put into a Becton-Dickinson red top vaeutainer tube which initially contained no reagents. Approximately one-half hour to 3 hours after withdrawing the blood, the plasma from my tube and the standardtube was removed. Most of the tests were performed with theTechnicon Auto-analyzer; the remainder being performed manually.
- lectins suitable for use in the invention include ricin (extract from the Castor bean), Concanavalin A (globular type proteins isolated in crystal form from jack bean meal as described by J. D. Sumner, Journal of Biological Chemistry, vol, 37, page 137 (1919)) and soybean hemagglutinin.
- a method of separating serum from the formed elements in a blood sample comprising the steps of:
- each of a plurality of formed elements in each clump are agglutinated with another formed element with a polymeric seam therebetween and agglutinated with a further formed element with a lectin link therebetween;
- a method of separating formed elements of the blood from serum comprising the steps of:
- a method of separating formed elements of the blood from serum comprising the steps of:
- a blood collection container containing a hemagglutinin and a positively charged polymer, said container having volumetric capacity sufficient to hold more than 30 cubic millimeters of blood.
Abstract
A process for separating plasma or serum from formed elements of the blood by adding a positively charged polymer and a lectin to a tube into which blood is drawn to effect precipitation of the formed elements of the plasma or serum.
Description
Sept. 2, 1975 United States Patent Greenspan METHOD OF AND APPARATUS FOR CHEMICALLY SEPARATING PLASMA 0R FOREIGN PATENTS OR APPLICATIONS SERUM FROM FORMED ELEMENTS OF BLOOD 9/1964 United Kingdom.....................
OTHER PUBLICATIONS August, A., Am. J. Med. Tech, Vol. 31, pp. 271278, 1965),
[75] Inventor: Donald .1. Greenspan, Riverside,
[73] Assignee: U.S. Medical Research and Development, Inc., Riverside, 'NJ. Primary Examiner-Alvin E. Tanenholtz May 21, 1973 Attorney, Agent, or Firm-Woodcock, Washburn, Kurtz & Mackiewicz [22] Filed:
Appl. No.: 362,454
ddmm ee n mw raom cw be m cbd V. mmmm m m u m rW e t S e a.mh
t mwm md m n v. a
E mh
A.m :m t awvd f I -ix Wbkn.
e 0 01 e cn emne n mml w lorf AePdo BM 2 OH C 3 MS Q a B 7 n U 0 On 1 .mN o Y M ed 9 s m Wm 1 mm m u m 9 L n C n I Z 5 C 8 U M H 6 5 l I {51] Int. Cl. GOln 33/16 195/1, 103.5 R, 127; 23/2585, 230 B; 210/538 15 Claims, 9 Drawing Figures [58] Field of Search................;
dn wmw...
METHOD OF AND APPARATUS FOR CHEMICALLY SEPARATING PLASMA OR SERUM FROM FORMED ELEMENTS OF BLOOD RELATED APPLICATIONS This is a continuation-in-part of application Ser. No. 207,577 filed Dec. 13, l97l now abandoned which is a continuation of application Ser. No. 847,469 filed Aug. 4, 1969 and now abondoned.
BACKGROUND OF THE INVENTION This invention relates to the separation of formed elements of the blood from plasma or serum.
At the present time, the separation of formed blood elements, e.g., red blood cells. from plasma or serum is accomplished almost entirely by mechanical separation techniques. Of the various mechanical separation tech- 'niques, centrifuging is most popular. However, me-
chanical separation techniques including centrifuging are cumbersome in that they require rather elaborate mechanical apparatus. Moreover, mechanical separation techniques may provide somewhat less than optimum plasma or serum yields. In addition, mechanical separation techniques can result in faulty plasma or serum analysis due to the time involved in transporting a blood sample to a centrifuging apparatus thereby delaying the separation of plasma or serum from the formed elements of the blood.
Ideally, separation of the cells from the plasma or serum should take place immediately thereby decreasing the amount of serum or plasma contamination by cell breakdown.
Chemically assisted mechanical separation techniques have been explored. One such technique, which is disclosed in British Pat. No. 969,741 Brewer, involves the use of agglutination, coagulation or precipitation of solid components of blood due to the presence of a phytohemagglutinin and mechanical stirring.
It has been found that the phytohemagglutinin alone, in the absence of stirring, will result in very slow precipitation of the blood cells which is believed to be due to the fact that clumps of blood cells which are formed are small and not particularly dense. Even with stirring, it is believed that any separation of serum from blood cells is too slow to be clinically feasible. More importantly, the stirring of the blood sample will itself cause cell breakdown and contaminate the results of serum or plasma analysis.
The use of lectins as hemagglutinins was described by Irvin E. Liener in a paper presented for discussion at the Seed Protein Conference sponsored by the Southern Utilization Research and Development Division. Agricultural Research Service, United States Department of Agriculture, New Orleans, La., Jan. 21-24, 1963 and printed in Economic Botany as an article entitled Seed Hemagglutinins". In this paper, there is considerable discussion of a theorized agglutinating mechanism involving receptor sites on the blood cells to which the lectin attaches. In this manner, two blood cells may be attached or clumped where their receptor sites are linked by the lectin.
Another chemically assisted mechanical separation technique has involved the use of an agglutinating agent comprising a positively charged polymer such as Polybrene (hexadimcthrine bromide). Such a use of Polybrene is disclosed in an article entitled A New Technic for Separation of Human Leukocytes" by Parvitz Lalezari, appearing in Blood, vol. 19, No. l, January, 1962 where the blood sample containing cells agglutinated by the Polybrene is centrifuged to effect precipitation. In an article by Anne August, appearing in the American Journal of Medical Technology, The Effect of Antiheparin Drugs on Human Blood, vol. 3 I, No. 4, July-August, 1965, Polybrene is also discussed as a means for inducing agglutination of blood cells.
Precipitation of the blood agglutinated with Polybrene into fairly large clumps is very slow without centrifuging. Moreover, the total amount of plasma or serum which may be obtained with Polybrene is relatively small. As a result, the total volume of serum which may be obtained in a given length of time is small as compared with the volume obtained utilizing the phytohemagglutinin described by Brewer. Moreover, the longer the blood cells remain in the plasma, the greater the contamination of the plasma so as to adversely affect the plasma analysis. In addition, a good deal of debris will remain in suspension in the plasma after precipitation. Any attempt to increase the concentration of Polybrene beyond a certain point for speeding precipitation will result in lysis of the blood cells. The reason for this lysis is not completely understood although it is believed that large concentrations of the positively charged polymer may result in collisions between the polymer and the cells which rupture the membrane of the cells. It is also possible that the large concentration of the positively charged polymer creates such substantial deformation of the cells as described by A. Katchalsky et al. in Biochimica [it Biophysica Acla, Basie Polyelectrolytes in Red Blood Cells", vol. 33, pp. l20l39, 1959, that the cells actually rupture.
SUMMARY OF THE INVENTION It is a general object of this invention to provide an improved method of chemically precipitating formed blood elements from plasma or serum.
It is a further object of this invention to employ a chemical separation technique which will not adversely effect the analysis of the plasma or' serum.
It is a further object of this invention to employ a chemical separation technique which assures separation of the formed elements of the blood from the serum or plasma within a short period of time.
It is also an object of this invention to employ a chemical separation technique which substantially prevents contamination of the plasma or serum.
It is still a further object of this invention to employ a chemical separation technique which yields substantial amounts of plasma or serum which has been separated from the formed elements of the blood.
In accordance with these and. other objects, two chemical reagents are utilized to cause agglutination of the formed elements of the blood and precipitation of these elements from the plasma or serum of the blood. The reagents comprise a positively charged polymer (basic polyelectrolyte) such as Polybrene, and a lectin (hemagglutinin plant extract), such as Bacto Phytohcmagglutinin P. which are added to a blood collection tube either during the manufacturing of the tube or at a later time by, for example, conventional needle insertion techniques. The blood taken from the donor is re ccived within the tube and the plasma is separated out as a result of the action of the above-mentioned chemi cals with the blood. The separation mechanism occurs spontaneously within one-half hour or less.
In accordance with one important aspect of the invention, the chemical reagents create large three dimensional dense clumps of blood cells which readily precipitate to the bottom of the collection tube. These clumps are desirable in that they are not easily broken apart by jarring the blood sample.
One explanation for the density, three-dimensionality and durability of these clumps. which is believed to be correct, is that a lectin has an increased agglutinating ability in the presence of a positively charged polymer. Since the formed elements of the blood are all negatively charged, they tend to repel one another and the probability of the lectin attached to a receptor site on one cell coming into contact with a receptor site of another cell to form a clump is lowered by this mutual repulsion. However, when the positively charged polymer is added to the blood sample and attracted to the negatively charged cells, the cells and polymer form neutralized masses which permit the lectin to more effectively agglutinate the blood cells since the cells are more likely to come into sufficiently close contact to permit the lectin to form links between the cells at receptor sites and cells within a clump are able to move into a densely packed configuration due to the absence of repulsion.
In addition to the neutralizing effect which allows the lectin to more effectively perform its agglutinating function, the positively charged polymer also provides its own agglutinating function. In other words, the single cell within the clump may be linked to one or more cells by the lectin while the same cell is linked to one or more other cells by the positively charged polymer. As a result of utilizing the two different types agglutinating aggulatinating agents, each cell is able to be attached to a greater number of cells than would be the case if only one of the two different types of agglutinating agents were utilized. This agglutinating mechanism also helps create increased density of cells in a clump and larger three dimensional clumps.
The large three dimensional clumps are essentially large net-like structures which are capable of dragging debris and fibrin down through the plasma. As the clumps collect at the bottom of the collection tube, a substantially integral structure is formed wherein all of the individual clumps are connected to one another.
Other objects and a fuller understanding of the invention will be had by referring to the following description in conjunction with the drawings.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. la is an elevational view ofa container immediately after blood, lectin and a positively charged polymer have been combined in accordance with this invention;
FIG. 1/; is an elevational view of the container and the contents of FIG. Ia approximately l minutes later;
FIG. 2a is an elevational view of a container immediately after blood and a lectin have been combined;
FIG. 2b is an elevational view of the container and the contents of FIG. 2a approximately minutes later;
FIG. 3a is an elevational view ofa container immediately after blood and a positively charged polymer have been combined;
FIG. 3b is an elevational view of the container of FIG. approximately 15 minutes later;
FIG. 4 is a schematic illustration of a clump of blood cells agglutinated in accordance with this invention;
FIG. 4a is a schematic illustration of a clump of blood cells agglutinated with a positively charged polymer; and
FIG. 4b is a schematic illustration of a clump of blood cells agglutinated with an organic hemagglutinin.
DESCRIPTION OF THE PREFERRED EMBODIMENT In the preferred embodiment of my invention, 5 milligrams (5mgs.) of Polybrene, a positively charged polymer hexadimethrine bromide), which is manufactured by Abbott Laboratories and 0.05cc of Bacto Phyt0- hemagglutinin P., a lectin (hemagglutinin plant extract) manufactured by Difco Company, are added to a 10cc Becton-Dickinson red top vacutainer (this tube initially contains no chemical reagents). The Bacto Phytohemagglutinin P. is manufactured in Sec vials and is assayed according to potency, not weight. It is understood that other vacuum tubes may be utilized in practicing the present invention, and that the abovementioned chemical reactants can be added during the manufacturing of the tube, or at a later time by, for example, conventional needle insertion techniques.
When blood which is taken from a patient or donor (approximately 9ccs of blood) enters the tube containing the positively charged polymer and the lectin, the formed blood elements are caused to separate from the plasma. This separation occurs due to the precipitation of large, dense, three dimensional clumps, which precipitation occurs within one-half hour or less so as to limit the contamination of the plasma or serum. One explanation for the size, density and three dimensionality of these clumps as compared with those obtained when lectin is utilized alone or Polybrene is utilized alone, is that the positively charged polymer Polybrene actually increases the agglutinating ability of the lectin. Since the formed elements of the blood are negatively charged, they tend to repel one another. The probability of the lectin attaching to a receptor site and one of the cells coming into contact with a receptor site of another cell to form a clump is lowered by this mutual repulsion. However, with the Polybrene being present, the negative cells are attracted to the Polybrene to create substantially electrically neutralized blood cellpolymer combinations. The lectin which attaches to the blood cell is then better able to agglutinate the blood cells and to clump since it does not have to overcome or otherwise work against the repulsion forces between the negatively charged blood cells since the blood cells have in effect been neutralized by the Polybrene. As a result, large, dense. three dimensional clumps of red blood cells are formed which rapidly precipitate to the bottom of the sample container. It is also important to note that the clumps of blood cells are very durable in that they do not break-up when the sample container is shaken, jarred or otherwise stirred. It is believed that this reflects the strength of the lectin agglutinating link between blood cells which no longer has to overcome the repulsion of the blood cells due to the neutralization by the Polybrene. The very dense nature of the clumps is to be attributable to the fact that the lectin is capable of upholding the blood cells in a closely linked relationship since the cells are no longer repelling one another again due to the neutralization by the positively charged polymer.
In order to enhance the precipitation of the formed elements of the blood. the long axis of the collection tube is placed parallel to the surface of acounter top. After the separation has taken place. the tube is gradually rotated manually to dislodge and put into solution any cells that remain on the glass part of the tube or stopper. A rotation of the tube also aids in filtering out the fibrin in the plasma to leave serum. The long axis of the tube is then placed perpendicular to the counter top.
When serum, rather than plasma, is desired, a substance can be added to inhibit the formation of fibrin or destroy the formation. A substance may also be added to cause clotting and precipitate the fibrin once it is present. For example, Fibrinolysin may be added to the collection tube to prevent the formation of fibrin, or a clotting agent such as thrombin may be added to accelerate clotting of the fibrin. The clumped blood cells which form a net-like structure effectively drag the fibrin downwardly with the clump of formed blood elements to in effect filter, at least to some degree, the fibrin out of the plasma.
In accordance with this one very important'aspeet of this invention, the use of a positively charged polymer in combination with a lectin produces a very rapid precipitation of the formed elements of the blood as compared with the rate of precipitation achieved using a lectin alone or a positively charged polymer alone. FIG. Ia shows a collection tube filled with a blood sample substantially immediately after the blood sample has been combined with Polybrene and Bacto Phytohemagglutinin P. Note that the formed elements of the blood near the bottom of the tube have begun to precipitate as can be seen from the light region 12 which represents plasma and a relatively low concentration of the formed blood elements. Precipitation results from the clumping of the formed blood elements, which clumps 14 have been formed on the wall of the tube 10. Microscopic examination of the clumps 14 indicates that they are substantially three dimensional structures comprising densely packed blood cells. After 15 minutes have passed. a layer 12' of plasma is achieved about 997: of the precipitated, formed elements of the blood. In this interim, a substantial number of the clumps on the wall of the tube 10 have slid down the wall through the plasma l2 and into the precipitated elements at the bottom of. the tube I0. Note that the clumps I4 which remain on the wall of the tube I0 are much larger than the clumps 14 which existed immediately after the blood had been combined with the Polybrene and the Bacto Phytohemagglutinin P.
FIG. 2a is a tube filled with a blood sample immediately after it has been combined with Bacto Phytohemagglutinin P. alone without the Polybrene being present. Once again, a layer of plasma 22 has begun to form near the top of the blood sample due to the immediate precipitation within the sample as a result of the clumps of blood elements which are created by the Bacto Phytohemagglutinin P. The clumps 24 on the walls of the tube 20 indicate that the Bacto Phytohemagglutinin P. produces much smaller clumps than those produced by the combination of the Polybrene and the Bacto Phytohemagglutinin P. Note that the rate of precipitation of the formed blood elements in the blood sample is much slower as depicted in FIG. 2b. layer of plasma 22' above 99% of the formed blood elcmcnts 6 at the end of lS minutes of precipitation has approximately half the height and volume .as that produced with the combination of Bacto Phytohemagglutinin P.
and Polybrene as depicted in FIG. lb. Note also that a' very large number of clumps 24 remain on the walls of the tube 20 after 15 minutes of precipitation. Furthermore, these clumps are of substantially the same size of the clumps 24 shown in FIG. 2a. In other words, the size of the clumps does not increase with time and the clumps do not become large enough to slide under the influence of gravity down the walls of the tube 20.
In a container 30 illustrated in FIG. 3a, Polybrene has just been added to a blood sample and precipitation has begun due to the agglutinating properties of the Polybrene which forms clumps 34 on the wall of the container 30. However, after 15 minutes, very little actual precipitation has occurred as shown in FIG. 3b wherein a very shallow layer of plasma 32' has formed above 99% of the blood cells. Note that this layer of plasma 32' formed by the Polybrene alone is much more shallow than the layer of plasma 22'. This is the case even though the initial clumps 34 and the subsequently formed clumps 34' which are quite fragile are larger than the clumps 24 and 24' which are formed with the use of the Bacto Phytohemagglutinin P. alone. Thus, the size of the clumps alone is not the key to precipitation of the blood cells to maximize the amount of plasma which can be obtained in a given amount of time.
Note further that the amount of plasma 12 obtained utilizing the combined agglutinating substances of the invention as shown in FIG. lb -is much more than the sum of the plasma obtained from utilizing either of those agglutinating agents alone as shown in FIGS. 2b and 3b. Actual measurements indicate that the amount of plasma 12' obtained utilizing this invention is approximately twice the amount of plasma obtained in utilizing the individual ingredients alone as depicted in FIGS. 2b and 3b. In other words, the result achieved in utilizing the combination: of the Polybrene and the Bacto Phytohemagglutinin P. is more than (approximately twice) the sum of the results achieved when utilizing these two ingredients separately.
This synergistic result indicates that the positively charged polymer and the lectin are interacting with one another to increase the rate of precipitation of the clumped blood cells. If thepoly'electrolyte and the organic lectin were not interacting but merely performing their own, independent agglutinating functions, the amount of plasma obtained in a-given amount of time utilizing the combination shou'ldbe equal to the sum of the plasma obtained when: the polyelectrolyte and the organic hemagglutinin are utilized alone.
An explanation of this interaction, which is believed to be correct in view of analyses performed after observing the results of this combination, will now be set forth with reference to FIG. 4 in conjunction with FIGS. 4a and 4b. FIG. 4 depicts a fragile clump of blood cells 40 which are linked on to one another by polymeric seams schematically depicted by the symbol .r. Note that each of the blood cells 40 is linked to at least one other blood cell by the polymeric seam .t and those blood cells 40 in the middle of the clump are linked totwo or three blood cells. However, each blood cell does have a substantial surface area which is not adjacent, in contact or connected to any other blood cell. An actual photograph of this type of polymeric bonding between the blood cells 40 is shownvon page 132 of the aforesaid Katchalsky ct al article entitled interactions of Basic *Polyelectrolytes with the Red Blood Cell. Since each cell 40- is" apparently capable of forming a link over a limited surface area, the resulting clump is n'otparticularly dense and voids 42 between the interconnectedcells 40 of clump clamp do .exist. The apparent inability-of the blood cells to form polymeric bonds along more of the surface area of each blood cell is' believed to be due to the fact that each negatively charged blood cell 40 is capable of being attracted to 'a limited number of positively charged polymers before the overall charge on the combination polymerblood cell is neutralized so as to prevent the attraction of that particular blood cell to any other positively charged polymers. 1
/ FIG. 4bdepictsa somewhat-smaller clump than that shown in FIG. 4a wherein the agglutination is achieved by a lectin.- As shown in FIG. 412, four cells 44 are linked or bonded as depicted by the symbol 0. The nature of the link is not particularly well understood but one very plausible explanation has been offered in the aforesaid Liener article which suggests that each blood cell includes a limited number of receptor sites to which a hemagglutinin such as Bacto PhytohemagglutininP. may be attached. Thus for two cells to attach themselves to oneanother utilizing an agglutinating agent such as Bacto Phytohe'magglutinin P., receptor sites on two different cells, must come in close proximity with the lectin therebetween. Then the'clumping of two cells 44 can occur. With this limitation on the ability of the cells 44 to clump, it is not suprising that each of the clumps42 as depicted in FIGS; 2a 'and 2b is rather small particularly in view of the repulsion between negatively charged blood cells. It'isalso not surprising that large areas of each of the cells 44 are not liked with any other cells due to the absence-or scarcity of receptor sites to form those links.
I When the positively charged polymer utilized to form the clump depicted in FIG. 4a is combinedwith the leetin hemagglutinin which forms the clump depicted in F-IG.4b, a dramaticdifference is observed in the nature of the clumps which'are formed as depicted in FIG. 4. As previously mentioned, it is believed that the positively charged polymer is attracted to the negatively charged-elements or cells so as to neutralize those cells and thereby permit the lectin which becomes attached to these cells to more effectively agglutinate these cells since the negative charge on the blood cells has been neutralized to preclude repulsion between these. cells. As shown in FIG. 4, the large, dense-clump of blood cells 46 is formed by a substantial number of individual blood cells which are completely surrounded by other blood cells and attached thereto by a plurality of lectin links 0. Increased number of lectin Iinksis. as previouslymentioned, due to the presence of thepositively charged polymer which neutralizes the negative charge on the cellsto preclude or at least'substantially reduce the repulsion therebetween. In addition. the positively charged polymer forms bonds or seams .r between blood cells'in the clump so as to perform the dual function of increasing the agglutinating ability of the lectin while also providing its own agglutinating function. When the clump in FIG.4 is analyzed, it will be seen that a substantial number of the blood cells in the clump have both a lectin link 0 and a polymer scam-A- with other blood cells.
As mentioned previously, the size of the clumps is not the only factt'irwhich determines the rate and extent of precipitation. If'itwere, the positively charged polymer alone would precipitate more rapidly than the organic lectin alone which'would be inconsistent-with the experimental results depicted in FIGS. 2b and 3b. In this connection, it isbelieved that the large, spider-like clumps of blood cells, an example of which is depicted in FIG. 4u,cr'eate a type of structure in the blood sample which is not only slow to precipitate but actually self-supporting due to the formation of fibrin soaasto account for the rather shallow layer of plasma 32' which is obtained when utilizing the positively charged polymer alone as depicted'in FIG. 3b. In'contrast, the combination of the positively charged polymer and the lectin achieves a dense cl-ump which precipitates 'rapidly and collapses into a rather limited area so as to obtain arather deep layer of plasma 12' as depicted in FIG. 119 due to the inhibition of fibrin formation. This explanation is borne out by microscopic examination of the blood cells at the bottom of the tube 10 when the combination of the positively charged polymer and the lectin is utilized. In particular; the blood cells at the bottom of the tube 10 as depicted in'FIG. lb seems to be a substantially unitary orintegra'l mass of compact blood cells which cling together when the tube 10 is tipped, shaken, jarred or otherwise disturbed. In'contrast, clumps ofblood cells precipitated to the bottom of containers 20'and are not'part of an -integral mass and se'paratefrom one another when the tube is disturbed.
In accordance with another important aspect of the invention, rapid precipitation of the blood cells is achieved while preserving the integrity of the tests results and analysis of the plasma.
The chart reproduced below represents actual test results of my system (M.'S.) compared with the presently used conventional centrifuged system (C.S.). A random selection of blood donors was used, and the blood samplings from the centrifuged system were obtained by using'the standard Becton-Dickinson tubes and reagents. In my system, Polybrene andBacto Phytohemaggliltinin P. were put into a Becton-Dickinson red top vaeutainer tube which initially contained no reagents. Approximately one-half hour to 3 hours after withdrawing the blood, the plasma from my tube and the standardtube was removed. Most of the tests were performed with theTechnicon Auto-analyzer; the remainder being performed manually.
TEST cs. M.S. TEST C.S. M.S.
Glucose 96 99 Chloride I04 I07 (C.S. I22 I26 I00 I03 Gray top 96 96- 1 97 9) tube used) lIl I12 I09 ll2 141 143 l 11 l 12 BUN 23 I 24 Sodium I33 I37 2U 2U I37 I34 16 I5 A I39 I38 22 Z2 I I40 I41 21 22 I 137 I36 3! 3l Total (1.) (7.9 Potas- 4.3 v 4.2 Protein (LI (n5 sium 4.() -4.(] i 7.0 7.2 3.0 2.9 6.8 I (w 4.6 4.7 (1.7 (1.5 4.2 4.4 Albumin 5.3 5.0 Calcium 10.4 10.3
4.6- 4.4 9.0 9.6 4.3 4.7 9.x, 9.x 4. k v 4.). I 9.4 9.5
-Continued TEST C.S. M.S. TEST C.S. M5.
5.0 4.9 9.0 9.1 SGPT 12 12 Phos- 4.1 3.9 8 9 phorus 3.3 3.2 9 8 3.9 3.7 24 26 2.5 2.5 Cholesterol 238 228 Uric 6.9 6.9 324 314 Acid 4.7 4.6 267 257 10.6 10.3 299 289 5.6 5.5 CO 26.5 26.5 Creati- 0.8 0.8 27.5 26.0 nine 0.8 0.8 27.5 26.0 1.9 1.9 23.0 22.5 1.4 1.4 26.0 25.0 1.0 1.1 Alk. Phos. 5.8 5.6 T-4 6.1 6.2 8.8 8.6 6.3 6.5 6.4 6.2 7.1 7.1 7.6 7.4 6.6 6.2 Serum Preg Positive Positive P.B.l. 7.7 7.9 nancy Test Negative Negative 6.8 6.9 Positive Positive 7.2 7.4 5.6 5.9 L.E. Latex Negative Negative T-3 1.12 1.00
Positive Positive 1.07 .98 Negative Negative 1.04 1.07 Negative Negative Hetcrophile Positive Positive Negative Negative Negative Negative Negative Negative Positive Positive C. Reactive Negative Negative Protein Positive Positive Negative Negative R. A. Latex Negative Negative Fixation Negative Negative Positive Positive The results reproduced in the above chart clearly indicate the reliability of the method of my invention as compared with the standard centrifuged separation method or any other presently employed method.
In the foregoing, two specific chemical substances have been mentioned for use in combination in practicing the invention, namely, the positively charged polymer or basic polyelectrolyte Polybrene (hexadimethrine bromide) and the organic hemagglutinin, Bacto Phytohemagglutinin P. It will of course be appreciated that other substances may be utilized in practicing the invention. For example, another polyelectrolyte such as polylysine hydrobromide, polyornithine hydrochloride, polyarginine sulfate, polyvinyl amine hydrobromide and protamine sulfate may be utilized. Other lectins suitable for use in the invention include ricin (extract from the Castor bean), Concanavalin A (globular type proteins isolated in crystal form from jack bean meal as described by J. D. Sumner, Journal of Biological Chemistry, vol, 37, page 137 (1919)) and soybean hemagglutinin.
1n the case of Polybrene and Bacto Phytohemagglutinin P. specific concentrations have been described These concentrations may vary but in general, it is preferred that a concentration be utilized which is equal to 50-95% of the concentration which will lysethe blood cells. This permits you to maximize the clumping and the precipitation without hemolysis. Thus it will be ap-' preciated that the actual physical amounts of the different substances may very. For example, ricin is a very" powerful agglutinating agent and very small amounts of ricin can result in hemolysis. Also, it will be appreciated that the invention may be utilized with blood samples of various sizes in excess of 30 cubic millimeters.
Although a specific embodiment of the invention has been described and others have been suggested, it will be understood that the invention embraces these and other embodiments as set forth in theappended claims.
What is claimed is:
l. A method of separating serum from the formed elements in a blood sample comprising the steps of:
combining a lectin hemagglutinin, a positively charged polymer and a blood sample in a container;
agglutinating the formed elements into clumps with said lectin and said positively charged polymer such that each of a plurality of formed elements in each clump are agglutinated with another formed element with a polymeric seam therebetween and agglutinated with a further formed element with a lectin link therebetween; and
precipitating said clumps to the bottom of the container to create a layer of plasma or serum above said formed elements. 2. The method of claim 1 wherein said clumps of formed elements are combined to form a substantially integral mass after precipitating.
3. The method of claim 2 wherein said clumps drag fibrin downwardly therewith while precipitating.
4. A method of separating formed elements of the blood from serum comprising the steps of:
combining a blood sample with a lectin hemagglutinin and a positively charged polymer in a container;
agglutinating the formed elements of the blood with said hemagglutinin and said positively charged polymer; and precipitating the agglutinated formed elements of the blood so as to form a layer of serum above 99% of the formed elements of the blood in a given length of time, said layer having a total volume greater then the sum of the volume in a layer of serum above 99% of all elements in a blood sample of the same size combined with said lectin alone after the same given length of time plus the volume in a layer of serum above 99% of all elements of the blood in a blood sample of the same size combined with said positively charged polymer after the same given length of time. p 5. A method of separating formed elements of the blood from serum comprising the steps of:
combining a blood sample with a lectin hemagglutinin and a positively charged polymer;
agglutinating the formed elements of the blood with said lectin and said positively charged polymer; and
precipitating the agglutinated formed elements of the blood at a rate in excess of the sum of the rates of precipitation achieved with said lectin alone in said blood sample and said positively charged polymer in said blood sample.
6. The method of separating plasma from formed elements of blood comprising the steps of:
collecting a sample of blood and placing the sample in a blood collection container; and
reacting said blood sample with a lectin hemagglutinin and a positively charged polymer whereby the formed blood elements separate from the plasma.
7. The method according to claim 6 wherein said positively charged polymer is Polybrene.
8. The method according to claim 6 wherein said hemagglutinin is Bacto .Phytohemagglutinin P.
12. The method according to claim 11 wherein said substance is thrombin.
13. In combination, a blood collection container containing a hemagglutinin and a positively charged polymer, said container having volumetric capacity sufficient to hold more than 30 cubic millimeters of blood.
14. The combination according to claim 13 wherein the container also contains a substance for inhibiting the formation of fibrin.
15. The combination of claim 13 wherein the said container is a vacuum type blood collection tube.
UNITED S'1A'll-1S PATENT omen CER'IIFICA'IE OF CORRECTION Patent No. 3902'964 Dated September 2 I 1975 Inventor) Donald J. Greenspan It is certified that: error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
Column 3, line 36, the word "aggulatinating is repeated twice. I
Column 7, line 3, the word "interactions' should he capital'iz ed; line 7, 'ai fter the word "clump"delete the word "clamp".
Signed and Sealed this sixteenth Day Of December 1975 [SEAL] Attest:
RUTH C. MASON C. MARSHALL DANN Arresting Officer Commissioner ofParents and Trademarks
Claims (15)
1. A METHOD OF SEPARATING SERUM FROM THE FORMED ELEMENTS IN A BLOOD SAMPLE COMPRISING THE STEPS OF: COMBINING A LECTIN HEMAGGLUTININ, A POSITIVELY CHARGE POLYMER AND A BLOOD SAMPLE IN A CONTAINER, AGGLUTINATING THE FORMED ELEMENTS INTO CLUMPS WITH SAID LECTIN AND SAID POSITIVELY CHARGED POLYMER SUCH THAT EACH OF A PLURALITY OF FORMED ELEMENTS IN EACH CLUMP ARE AGGLUTINED WITH ANOTHER FORMED ELEMENT WITH A POLYMERIC
2. The method of claim 1 wherein said clumps of formed elements are combined to form a substantially integral mass after precipitating.
3. The method of claim 2 wherein said clumps drag fibrin downwardly therewith while precipitating.
4. A method of separating formed elements of the blood from serum comprising the steps of: combining a blood sample with a lectin hemagglutinin and a positively charged polymer in a container; agglutinating the formed elements of the blood with said hemagglutinin and said positively charged polymer; and precipitating the agglutinated formed elements of the blood so as to form a layer of serum above 99% of the formed elements of the blood in a given length of time, said layer having a total volume greater then the sum of the volume in a layer of serum above 99% of all elements in a blood sample of the same size combined with said lectin alone after the same given length of time plus the volume in a layer of serum above 99% of all elements of the blood in a blood sample of the same size combined with said positively charged polymer after the same given length of time.
5. A method of separating formed elements of the blood from serum comprising the steps of: combining a blood sample with a lectin hemagglutinin and a positively charged polymer; agglutinating the formed elements of the blood with said lectin and said positively charged polymer; and precipitating the agglutinated formed elements of the blood at a rate in excess of the sum of the rates of precipitation achieved with said lectin alone in said blood sample and said positively charged polymer in said blood sample.
6. The method of separating plasma from formed elements of blood comprising the steps of: collecting a sample of blood and placing the sample in a blood collection container; and reacting said blood sample with a lectin hemagglutinin and a positively charged polymer whereby the formed blood elements separate from the plasma.
7. The method according to claim 6 wherein said positively charged polymer is Polybrene.
8. The method according to claim 6 wherein said hemagglutinin is Bacto Phytohemagglutinin P.
9. The method of claim 6 wherein the hemagglutinin and the positively charged polymer are simultaneously reacted with the blood.
10. The method according to claim 6 wherein said blood collection container is hollow cylindrical in configuration and has a longitudinal axis and comprising the additional step of disposing said blood collection container with its longitudinal axis in a substantially horizontal plane to enhance precipitation of the formed blood elements from the plasma.
11. The method according to claim 6 to produce serum, including the further step of adding a substance for inhibiting the formation of fibrin.
12. The method according to claim 11 wherein said substance is thrombin.
13. In combination, a blood collection container containing a hemagglutinin and a posItively charged polymer, said container having volumetric capacity sufficient to hold more than 30 cubic millimeters of blood.
14. The combination according to claim 13 wherein the container also contains a substance for inhibiting the formation of fibrin.
15. The combination of claim 13 wherein the said container is a vacuum type blood collection tube.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US362454A US3902964A (en) | 1971-12-13 | 1973-05-21 | Method of and apparatus for chemically separating plasma or serum from formed elements of blood |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20757771A | 1971-12-13 | 1971-12-13 | |
US362454A US3902964A (en) | 1971-12-13 | 1973-05-21 | Method of and apparatus for chemically separating plasma or serum from formed elements of blood |
Publications (1)
Publication Number | Publication Date |
---|---|
US3902964A true US3902964A (en) | 1975-09-02 |
Family
ID=26902375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US362454A Expired - Lifetime US3902964A (en) | 1971-12-13 | 1973-05-21 | Method of and apparatus for chemically separating plasma or serum from formed elements of blood |
Country Status (1)
Country | Link |
---|---|
US (1) | US3902964A (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4097237A (en) * | 1977-03-04 | 1978-06-27 | Technicon Instruments Corporation | Determination of cells in blood |
US4366244A (en) * | 1978-07-04 | 1982-12-28 | Laboratoires Goella | Method for measuring serum cholesterol |
EP0050660B1 (en) * | 1980-04-28 | 1986-07-23 | Montefiore Hospital and Medical Center | Antibody detection process and reagents therefor |
EP0225703A2 (en) * | 1985-11-01 | 1987-06-16 | Becton Dickinson and Company | Method of improving the demarcation and separation of cells in centrifuged blood samples |
US4933092A (en) * | 1989-04-07 | 1990-06-12 | Abbott Laboratories | Methods and devices for the separation of plasma or serum from whole blood |
US4940668A (en) * | 1985-11-01 | 1990-07-10 | Becton Dickinson And Company | Method for increasing agglutination of groups of cells to produce improved cell layer interface in centrifuged blood sample |
US4945054A (en) * | 1982-05-19 | 1990-07-31 | Commissariat A L'energie Atomique | Process for the separation and purification of proteases and antiproteases of blood clotting, as well as of the protease/antiprotease complex |
US4994192A (en) * | 1990-01-16 | 1991-02-19 | Eastman Kodak Company | Amine polymers as coagulator accelerators in blood phase separation |
US5064541A (en) * | 1989-04-07 | 1991-11-12 | Abbott Laboratories | Devices and methods for the collection of a predetermined volume of plasma or serum |
EP0570141A1 (en) * | 1992-05-08 | 1993-11-18 | Becton, Dickinson and Company | Additive having dual surface chemistry and blood collection assembly containing same |
US5435970A (en) * | 1989-12-18 | 1995-07-25 | Environmental Diagnostics, Inc. | Device for analysis for constituents in biological fluids |
US5725774A (en) * | 1995-04-07 | 1998-03-10 | Lxn Corp. | Whole blood separation method and devices using the same |
US5776357A (en) * | 1995-08-28 | 1998-07-07 | Sekisui Kagaku Kogyo Kabushiki Kaisha | Serum or plasma separating compositions |
US5877028A (en) * | 1991-05-29 | 1999-03-02 | Smithkline Diagnostics, Inc. | Immunochromatographic assay device |
US5919419A (en) * | 1994-02-22 | 1999-07-06 | Orion-yhtyma Oy | Analyzer cuvette, method and diagnostic test kit for determination of analytes in whole blood samples |
US5998220A (en) * | 1991-05-29 | 1999-12-07 | Beckman Coulter, Inc. | Opposable-element assay devices, kits, and methods employing them |
US6008059A (en) * | 1995-05-09 | 1999-12-28 | Beckman Coulter, Inc. | Devices and methods for separating cellular components of blood from liquid portion of blood |
US6168956B1 (en) | 1991-05-29 | 2001-01-02 | Beckman Coulter, Inc. | Multiple component chromatographic assay device |
US6238578B1 (en) | 1996-12-09 | 2001-05-29 | Sherwood Services Ag | Method for dispensing separator gel in a blood collection tube |
US20050139547A1 (en) * | 2003-12-24 | 2005-06-30 | Dimitrios Manoussakis | Plasma on demand tube |
WO2007092028A2 (en) | 2005-04-08 | 2007-08-16 | Medical Discovery Partners Llc | Method for enriching rare cell subpopulations from blood |
US20130183655A1 (en) * | 2011-07-05 | 2013-07-18 | Becton, Dickinson And Company | Coagulation controlling agents and devices comprising the same |
US10190091B2 (en) | 2013-04-15 | 2019-01-29 | Cells 4 Life Group Llp | Methods of cell separation |
US20200238201A1 (en) * | 2019-01-24 | 2020-07-30 | Sumitomo Rubber Industries, Ltd. | Specific cell fractionating and capturing methods |
US11786894B2 (en) | 2020-10-29 | 2023-10-17 | Ashim Gupta | Whole blood separator device and method of use |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB969741A (en) * | 1963-06-14 | 1964-09-16 | John Hanna Brewer | Apparatus and method for separating certain components from blood |
-
1973
- 1973-05-21 US US362454A patent/US3902964A/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB969741A (en) * | 1963-06-14 | 1964-09-16 | John Hanna Brewer | Apparatus and method for separating certain components from blood |
Non-Patent Citations (1)
Title |
---|
August, A., Am. J. Med. Tech., Vol. 31, pp. 271-278, (1965) * |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4097237A (en) * | 1977-03-04 | 1978-06-27 | Technicon Instruments Corporation | Determination of cells in blood |
US4366244A (en) * | 1978-07-04 | 1982-12-28 | Laboratoires Goella | Method for measuring serum cholesterol |
EP0050660B1 (en) * | 1980-04-28 | 1986-07-23 | Montefiore Hospital and Medical Center | Antibody detection process and reagents therefor |
US4945054A (en) * | 1982-05-19 | 1990-07-31 | Commissariat A L'energie Atomique | Process for the separation and purification of proteases and antiproteases of blood clotting, as well as of the protease/antiprotease complex |
EP0225703A3 (en) * | 1985-11-01 | 1987-07-22 | Wardlaw, Stephen Clark | Method of improving the demarcation and separation of cells in centrifuged blood samples |
US4940668A (en) * | 1985-11-01 | 1990-07-10 | Becton Dickinson And Company | Method for increasing agglutination of groups of cells to produce improved cell layer interface in centrifuged blood sample |
EP0225703A2 (en) * | 1985-11-01 | 1987-06-16 | Becton Dickinson and Company | Method of improving the demarcation and separation of cells in centrifuged blood samples |
US4695553A (en) * | 1985-11-01 | 1987-09-22 | Becton Dickinson And Co., Inc. | Method for increasing agglutination of groups of cells to produce improved cell layer interface in centrifuged blood sample using antibodies |
US4933092A (en) * | 1989-04-07 | 1990-06-12 | Abbott Laboratories | Methods and devices for the separation of plasma or serum from whole blood |
US5064541A (en) * | 1989-04-07 | 1991-11-12 | Abbott Laboratories | Devices and methods for the collection of a predetermined volume of plasma or serum |
US5435970A (en) * | 1989-12-18 | 1995-07-25 | Environmental Diagnostics, Inc. | Device for analysis for constituents in biological fluids |
US4994192A (en) * | 1990-01-16 | 1991-02-19 | Eastman Kodak Company | Amine polymers as coagulator accelerators in blood phase separation |
US6168956B1 (en) | 1991-05-29 | 2001-01-02 | Beckman Coulter, Inc. | Multiple component chromatographic assay device |
US6017767A (en) * | 1991-05-29 | 2000-01-25 | Beckman Coulter, Inc. | Assay device |
US5998220A (en) * | 1991-05-29 | 1999-12-07 | Beckman Coulter, Inc. | Opposable-element assay devices, kits, and methods employing them |
US5877028A (en) * | 1991-05-29 | 1999-03-02 | Smithkline Diagnostics, Inc. | Immunochromatographic assay device |
JPH0776769B2 (en) | 1992-05-08 | 1995-08-16 | ベクトン・ディッキンソン・アンド・カンパニー | Additive with two surface chemistries for blood collection container and assembly device containing the same |
EP0570141A1 (en) * | 1992-05-08 | 1993-11-18 | Becton, Dickinson and Company | Additive having dual surface chemistry and blood collection assembly containing same |
US5919419A (en) * | 1994-02-22 | 1999-07-06 | Orion-yhtyma Oy | Analyzer cuvette, method and diagnostic test kit for determination of analytes in whole blood samples |
US5762871A (en) * | 1995-04-07 | 1998-06-09 | Lxn Corp. | Multi-layer test device for analyzing the concentration of analyte in a blood sample |
US5725774A (en) * | 1995-04-07 | 1998-03-10 | Lxn Corp. | Whole blood separation method and devices using the same |
US6008059A (en) * | 1995-05-09 | 1999-12-28 | Beckman Coulter, Inc. | Devices and methods for separating cellular components of blood from liquid portion of blood |
US6069014A (en) * | 1995-05-09 | 2000-05-30 | Beckman Coulter, Inc. | Devices and methods for separating cellular components of blood from liquid portion of blood |
US6197598B1 (en) | 1995-05-09 | 2001-03-06 | Beckman Coulter, Inc. | Devices and methods for separating cellular components of blood from liquid portion of blood |
US5776357A (en) * | 1995-08-28 | 1998-07-07 | Sekisui Kagaku Kogyo Kabushiki Kaisha | Serum or plasma separating compositions |
US20010007315A1 (en) * | 1995-12-12 | 2001-07-12 | Fiehler William R. | Method and apparatus for dispensing separator gel in a blood collection tube |
US6238578B1 (en) | 1996-12-09 | 2001-05-29 | Sherwood Services Ag | Method for dispensing separator gel in a blood collection tube |
US7500569B2 (en) | 2003-12-24 | 2009-03-10 | Becton, Dickinson And Company | Plasma on demand tube |
US20050139547A1 (en) * | 2003-12-24 | 2005-06-30 | Dimitrios Manoussakis | Plasma on demand tube |
WO2007092028A2 (en) | 2005-04-08 | 2007-08-16 | Medical Discovery Partners Llc | Method for enriching rare cell subpopulations from blood |
US20090081632A1 (en) * | 2005-04-08 | 2009-03-26 | Medical Discovery Partners Llc | Method for Enriching Rare Cell Subpopulations From Blood |
US8263404B2 (en) | 2005-04-08 | 2012-09-11 | Medical Discovery Partners Llc | Method for enriching rare cell subpopulations from blood |
US20130183655A1 (en) * | 2011-07-05 | 2013-07-18 | Becton, Dickinson And Company | Coagulation controlling agents and devices comprising the same |
JP2014524027A (en) * | 2011-07-05 | 2014-09-18 | ベクトン・ディキンソン・アンド・カンパニー | Coagulation control agent and apparatus including the same |
US9949473B2 (en) * | 2011-07-05 | 2018-04-24 | Becton, Dickinson And Company | Coagulation controlling agents and devices comprising the same |
US10190091B2 (en) | 2013-04-15 | 2019-01-29 | Cells 4 Life Group Llp | Methods of cell separation |
US20200238201A1 (en) * | 2019-01-24 | 2020-07-30 | Sumitomo Rubber Industries, Ltd. | Specific cell fractionating and capturing methods |
US11614440B2 (en) * | 2019-01-24 | 2023-03-28 | Sumitomo Rubber Industries, Ltd. | Specific cell fractionating and capturing methods |
US11786894B2 (en) | 2020-10-29 | 2023-10-17 | Ashim Gupta | Whole blood separator device and method of use |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3902964A (en) | Method of and apparatus for chemically separating plasma or serum from formed elements of blood | |
Crawford | The presence of contractile proteins in platelet microparticles isolated from human and animal platelet‐free plasma | |
RU96122161A (en) | METHOD FOR SELECTING POPULATIONS OR SUB-POPULATIONS OF SAMPLE | |
US4487700A (en) | Method and apparatus for separating lymphocytes from anticoagulated blood | |
EP0305337B1 (en) | Method for the detection of antigens and/or antibodies, and a kit for carrying out the method | |
WO2001083002A2 (en) | Whole blood separator apparatus and method of use | |
US3986506A (en) | Apparatus for separation of cryoprecipitate from blood plasma and method | |
US3146163A (en) | Apparatus for separating certain components from blood | |
CN100492006C (en) | Filter apparatus and blood detection container | |
JPS5812061B2 (en) | Method and apparatus for concentrating and separating pathogenic microorganisms | |
NL8403352A (en) | INDUCTION OF IMMUNE RESPONSE BY IMMUNIZING WITH ENCAPSULATED ANTIGEN CELLS. | |
US11745182B2 (en) | Collapsible centrifugation vial system and method | |
US4038150A (en) | Sample mixing and centrifugation apparatus | |
US4164449A (en) | Surface separation technique for the detection of microbial pathogens | |
WO2014127314A1 (en) | Devices and methods for purification of biological cells | |
JP3325620B2 (en) | Method of performing density gradient centrifugation and the insert for stratification used for it | |
EP1265710A2 (en) | Method and apparatus for processing substances in a single container | |
US3843444A (en) | Membrane separation process | |
US3828103A (en) | Indirect hemagglutination test with simultaneous absorption of heterologous antibodies | |
US3840655A (en) | Diagnostic methods and reagents for infectous mononucleosis | |
EP1341467A2 (en) | Method for precipitating red blood cells | |
CN112501108B (en) | Method for separating large and small stinging capsules of stinging hand of jellyfish and extracting venom | |
DE3725504A1 (en) | METHOD AND DEVICE FOR DETECTING ANTIBODIES AND ANTIGENES | |
Salmi | Characteristics of gel precipitating antigens of rubella virus | |
JPH04182398A (en) | Production of crystal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GREENSPAN, DONALD J., 235 PAVILION AVE., RIVERSIDE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:GREEN SCIENTIFICS, INC. A NJ CORP.;REEL/FRAME:003914/0310 Effective date: 19810609 Owner name: GREENSPAN, DONALD J., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GREEN SCIENTIFICS, INC. A NJ CORP.;REEL/FRAME:003914/0310 Effective date: 19810609 |